Publication | Closed Access

Metergoline blocks the behavioral and neuroendocrine effects of orally administered m-chlorophenylpiperazine in patients with obsessive-compulsive disorder

Neuroendocrine EffectsPsychoactive DrugPsychiatryBehavioral NeuroscienceAddictionMedicineBehavioral PharmacologyObsessive-compulsive DisorderBehavioural PharmacologyPsychopharmacologyNeuropharmacologyCompulsive BehaviorSocial SciencesPharmacologyPsychopathology